Franklin Genomic Advancements ETF

Premium/discount is how far the market price trades above (+) or below (−) the fund's net asset value (reported in USD).

3-year risk statistics are not currently available for this fund.

Risk statistics are 3-year, month-end-based.

Average daily share volume over each trailing window. Spread is the average bid-ask spread as a percentage of price — lower means cheaper to trade.

Fees & expenses

Category

Equity – SectorHealth Care

Asset class

Equity

Strategy

Active

Themes

Genomics

Sector

Health Care

Issuer

Franklin Advisers, Inc.

Branding

Franklin Templeton

Similar ETFs

Funds sharing the same category or exposures.

• ARKGUS

  ARK Genomic Revolution ETF

  Same category · Same sector · genomics

  $2.17B0.750%+84.19%
• GNOMUS

  Global X Genomics & Biotechnology ETF

  Same category · Same sector · genomics

  $105.69M0.500%+54.60%
• XLVUS

  State Street® Health Care Select Sector SPDR® ETF

  Same category · Same sector

  $43.92B0.080%+11.63%
• IBBUS

  iShares Biotechnology ETF

  Same category · Same sector

  $10.64B0.440%+24.41%
• VGTUS

  Vanguard Information Technology Index Fund

  Same group

  $170.65B0.090%+34.36%
• XLKUS

  State Street® Technology Select Sector SPDR® ETF

  Same group

  $127.79B0.080%+36.81%

Frequently asked questions

What is HELX's expense ratio?

Franklin Genomic Advancements ETF charges a net expense ratio of 0.500%.

How large is Franklin Genomic Advancements ETF?

HELX holds $33.20M in assets under management.

What index does HELX track?

Franklin Genomic Advancements ETF tracks Russell 3000 as its primary benchmark.

When did HELX launch?

Franklin Genomic Advancements ETF launched on February 25, 2020.

What currency does HELX trade in?

HELX trades in USD on Cboe BZX U.S. Equities Exchange.

Fund information